Fort Washington Investment Advisors Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 5.2% during the first quarter, purchasing an additional 4,559 shares to hold a total position of 92,090 shares valued at $32.4 million. This move aligns with several other institutional investors who recently...
Piper Sandler and Morgan Stanley have reaffirmed their Overweight ratings on Amgen Inc. (NASDAQ: AMGN), citing the strength of its pharmaceutical pipeline and potential in obesity therapeutics. Piper Sandler maintained a $427 price target, while Morgan Stanley raised its objective to $340 from $332 following...
Amgen Inc. faces a significant legal setback after a Delaware federal jury ruled in June 2026 that the company willfully infringed on Harbour BioMed's Grosveld patent regarding antibody technology. The jury awarded Harbour BioMed exactly $20,203,704 in damages, with analysts noting that US law allows...
Amgen (AMGN) stock is currently trading at $344.72, which a recent analysis suggests is approximately 2.1% undervalued relative to a calculated fair value of $352.23. This valuation assessment follows a significant legal development where Harbour BioMed's jury found Amgen guilty of willful patent infringement, awarding...
Amgen Inc. (AMGN) begins the week with muted news flow, as investors shift focus toward upcoming quarterly earnings expected in late July 2026 and key pipeline developments in obesity, oncology, and inflammation sectors. Shares closed at $337.60 on June 18, 2026, trading slightly lower in...
A U.S. jury in Delaware has ruled that Amgen Inc. and its subsidiary Teneobio willfully infringed a key patent held by Harbour BioMed regarding antibody-discovery technology. The verdict, delivered following a trial that began June 8, 2026, found the defendants liable for patent infringement related...
Amgen (AMGN) is the subject of recent market activity driven by a congressional portfolio shift and insider trading data. Representative David J. Taylor added Amgen shares to his holdings in early June, interpreted by observers as a preference for stable cash-flow generators amidst broader market...
Amgen announced that the European Commission has granted marketing authorization for IMDYLLTRA (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. This approval is based...
Zacks Equity Research analysts released new reports on Amgen Inc. (AMGN) alongside other major stocks, highlighting the biotech giant's recent financial performance and strategic outlook. The company beat first-quarter estimates for both earnings and sales, driven by key medicines such as Evenity, Repatha, Uplizna, Imdelltra,...
Amgen shareholders voted to re-elect all 12 director nominees at their annual meeting held on May 19, 2026, ensuring continuity in board leadership and governance. In addition to the board re-election, investors approved the company's executive compensation program on an advisory basis, indicating sustained support...
Amgen Inc. (AMGN) is drawing attention from options traders due to significant implied volatility observed on the May 15, 2026, $200 call option, which ranks among the highest for equity options today. High implied volatility indicates that the market expects substantial price movement in the...
Amgen Inc. (AMGN) is experiencing heightened activity in the options market, specifically with the May 15, 2026 $200 Call option showing elevated implied volatility compared to other equity options currently trading. High implied volatility indicates that traders are anticipating a significant price movement in either...
Amgen Inc. (NASDAQ:AMGN) saw increased interest from institutional investors following the fourth quarter filings, with Nicholas Company Inc. acquiring a new position valued at approximately $5.373 million for 16,415 shares. Other major institutional changes include Robeco Institutional Asset Management B.V., which increased its stake by...
Amgen Inc. reported first-quarter 2026 earnings on April 30, 2026, which demonstrated broad-based growth across its diversified pharmaceutical portfolio. The results highlight the company's resilience and momentum in a competitive market, spanning key therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, and neuroscience....
Amgen's shares closed at $361.13, reflecting a 1.4% decline that significantly underperformed major indices like the S&P 500 and Nasdaq which posted gains earlier in the day. Over the past month, Amgen has dropped 0.8%, falling more sharply than the broader medical sector or the...
Amgen Inc. (AMGN) is being compared with Royalty Pharma (RPRX) in an analysis from Zacks Investment Research to determine which stock represents the better value option for investors interested in the Medical-Biomedical and Genetics sectors. The article utilizes Zacks Rank and Style Scores, specifically focusing...
Amgen has announced an additional $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico. This site, established in 1992, is currently one of the largest biologics manufacturing facilities in the world and supplies medicines to over 60 countries. With this new...
Guggenheim Securities has reduced its price target on Amgen (NASDAQ: AMGN) from $351 to $340, maintaining a Neutral rating following the company's Q1 2026 earnings release. While the firm updated its model rather than changing its fundamental thesis, the revision reflects Wall Street's growing caution...
Amgen Inc (AMGN) reported first-quarter earnings and provided an upgraded forward outlook, driven by strong performance in its core growth franchises despite headwinds from legacy product decline and regulatory uncertainties. Total product sales grew 4% year over year, totaling approximately $13.7 billion, fueled primarily by...
Amgen Inc (AMGN) held its Q1 earnings call with management emphasizing solid commercial momentum, upgraded guidance, and a strengthening late-stage pipeline despite visible headwinds. The company reported modest 4% overall sales growth in the first quarter, which was powered by high-growth franchises that grew 24%...
